SBC Medical Reports Q1 Revenue of $43M, Below Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 14 2026
0mins
Reports Q1 revenue $43M, consensus $41.66M. CEO Yoshiyuki Aikawa said, "For Q1 of FY26, SBC Medical reported revenue of $43 million, representing a 9% year-over-year decline. This decrease was primarily attributable to a strategic structural reform implemented in April 2025, involving a revision of the franchise fee structure. Excluding this structural change, the performance of our core business remained solid. In terms of profitability, our net income margin was 26%, and our EBITDA margin remained at a high level of 43%. Looking ahead, we will continue to promote our multi-brand strategy in the aesthetic dermatology field, expand our non-aesthetic medical business, and strengthen our operational foundation in overseas markets. In addition, we will pursue opportunities in the longevity market and further enhance our services through the utilization of AI, with the goal of building a sustainable and continuously growing healthcare platform."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SBC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SBC
Wall Street analysts forecast SBC stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.100
Low
9.00
Averages
9.00
High
9.00
Current: 3.100
Low
9.00
Averages
9.00
High
9.00
About SBC
SBC Medical Group Holdings Incorporated is a management company, which owns, operates, and provides management services to cosmetic treatment centers. The Company is primarily focused on providing comprehensive management services to franchisee clinics, including, but not limited to, advertising and marketing needs across various platforms, staff management, booking reservations for franchisee clinic customers, assistance with franchisee employee housing rentals and facility rentals, construction and design of franchisee clinics, medical equipment and medical consumable's procurement (resale), the provision of cosmetic products to franchisee clinics for resale to clinic customers, licensure of the use of patent-pending and non-patented medical technologies, trademark and brand use, IT software solutions (including but not limited to remote medical consultations), management of the franchisee clinic’s customer rewards program, and payment tools for the franchisee clinics.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SBC Medical Opens New Dermatology Section in Thailand
- New Business Launch: SBC Medical, in partnership with BLEZ ASIA, inaugurates a new aesthetic dermatology section at BLEZ CLINIC in Bangkok's Asok district, with services set to commence in June 2026, marking a significant milestone in the company's Thai market efforts.
- Market Opportunity: With Thailand's aesthetic healthcare market experiencing rapid growth, SBC Medical aims to leverage its collaboration with BLEZ ASIA to meet the high-quality service demands of Japanese expatriates, thereby enhancing its competitive position.
- Service Features: The new dermatology section will focus on pico laser treatments for pigmentation and spot removal, ensuring a safe and professional medical environment for Japanese expatriates, which is crucial for building customer trust.
- Strategic Expansion Plan: Following the establishment of a strong reputation in Asok, SBC Medical plans to gradually expand into the broader Thai market and across ASEAN, committed to delivering high-quality medical services that cater to local needs and create new market value.
See More
SBC Medical Group Q1 2026 Earnings Call Insights
- Revenue Decline Analysis: Total revenues for Q1 2026 were $43 million, reflecting a 9% year-over-year decline primarily due to fee structure revisions implemented in April last year, which negatively impacted franchising revenue by $6.2 million and management services revenue by $2.4 million, totaling an $8.7 million decrease, indicating challenges in revenue structure adjustments.
- Profitability Decline: Net income decreased year-over-year, partly due to a one-time life insurance gain of $8.7 million in the prior year; however, excluding the impact of fee structure revisions, underlying revenue grew by 11% year-over-year, demonstrating potential business resilience.
- AI Strategy Advancement: The company is promoting an AI initiative aimed at driving top-line growth through enhanced customer experiences while also enabling a leaner, more efficient organization, with management expressing optimism about future growth as the impact of fee structure adjustments rolls off.
- Cash Flow and Investment Priorities: Management emphasized that while the current share repurchase program is not a priority, the company has a strong cash position and plans to prioritize growth investments, particularly in seeking M&A opportunities within the competitive Japanese aesthetic market.
See More
SBC Medical Group Q1 Earnings Report
- Earnings Highlights: SBC Medical Group reported a Q1 GAAP EPS of $0.11, reflecting resilience in the current market despite a 9.1% year-over-year decline, indicating ongoing profitability amidst challenges.
- Revenue Performance: The company generated $43 million in revenue for Q1, down 9.1% year-over-year and missing market expectations by $5.87 million, highlighting challenges in revenue growth that could impact investor confidence moving forward.
- Secondary Offering Announcement: SBC Medical announced a secondary offering of 3.1 million shares by a selling stockholder, aimed at strengthening its capital structure and providing funding for future expansion, demonstrating a proactive approach to market opportunities.
- Analyst Ratings: While the Q1 GAAP EPS of $0.14 beat expectations by $0.03, the revenue of $39.57 million fell short of projections, reflecting a cautious market sentiment regarding the company's future performance and potential stock price implications.
See More
SBC Medical Reports Q1 2026 Financial Results with Significant Declines
- Revenue Decline: In Q1 2026, total revenues were $43 million, reflecting a 9% year-over-year decrease primarily due to a franchise fee structure reform implemented in April 2025, indicating challenges in revenue growth for the company.
- Significant Net Income Drop: Net income attributable to SBC Medical was $11 million, a 47% year-over-year decline, with a net income margin of 26%, down 19 percentage points from the previous year, highlighting a substantial weakening in profitability.
- Customer Growth and Retention: Despite revenue challenges, the number of customers reached 6.76 million over the past twelve months, a 10% year-over-year increase, with a repeat visit rate of 72%, indicating the company's continued market appeal in customer retention.
- Future Strategic Direction: The company plans to advance its multi-brand strategy, expand its non-aesthetic medical business, and enhance service quality through AI utilization, aiming to adapt to market changes and achieve sustainable growth.
See More
European Stock Market Volatility and Undervalued Stocks Analysis
- Market Volatility Analysis: The European stock market has recently experienced volatility, with the pan-European STOXX Europe 600 Index posting modest gains as investor sentiment was buoyed by easing geopolitical tensions and strong corporate earnings, indicating a search for stability amidst uncertainty.
- Undervalued Stocks Identification: In the current market environment, identifying undervalued stocks is crucial, particularly those potentially trading below their intrinsic value, allowing investors to optimize their portfolios through these opportunities.
- SNGN Romgaz Financial Overview: SNGN Romgaz SA has a market cap of RON 52.03 billion, with full-year sales reaching RON 8.03 billion and net income at RON 3.35 billion in 2022, while projected annual growth of 10.9% indicates strong competitiveness in the Romanian market.
- Alleima Future Outlook: Alleima AB is currently trading at SEK 83.70, significantly below its estimated future cash flow value of SEK 112.76, and despite a decline in first-quarter sales to SEK 4.58 billion, it is expected to grow at an annual rate of 28%, far exceeding the Swedish market's average of 8.9%.
See More
SBC Medical Group to Release Q1 2026 Financial Results
- Earnings Release Schedule: SBC Medical Group plans to release its financial results for the first quarter ended March 31, 2026, before the U.S. market opens on May 14, 2026, which is expected to provide investors with key financial data and operational performance insights.
- Conference Call Details: Management will host an earnings conference call on the same day at 8:30 a.m. Eastern Time, followed by a Q&A session with analysts and investors, aimed at enhancing transparency and fostering engagement with stakeholders.
- Company Background: SBC Medical Group is a Medical Services Organization providing management support across various healthcare fields, including aesthetic healthcare and orthopedics, actively expanding its presence in the U.S. and Asia, demonstrating its commitment to a global strategy.
- NASDAQ Listing Achievement: Since its listing on NASDAQ in September 2024, SBC Medical Group was included in the Russell 3000® Index in June 2025, marking an increase in its recognition and influence within the U.S. equity market.
See More
SBC Medical Opens New Dermatology Section in Thailand
- New Business Launch: SBC Medical, in partnership with BLEZ ASIA, inaugurates a new aesthetic dermatology section at BLEZ CLINIC in Bangkok's Asok district, with services set to commence in June 2026, marking a significant milestone in the company's Thai market efforts.
- Market Opportunity: With Thailand's aesthetic healthcare market experiencing rapid growth, SBC Medical aims to leverage its collaboration with BLEZ ASIA to meet the high-quality service demands of Japanese expatriates, thereby enhancing its competitive position.
- Service Features: The new dermatology section will focus on pico laser treatments for pigmentation and spot removal, ensuring a safe and professional medical environment for Japanese expatriates, which is crucial for building customer trust.
- Strategic Expansion Plan: Following the establishment of a strong reputation in Asok, SBC Medical plans to gradually expand into the broader Thai market and across ASEAN, committed to delivering high-quality medical services that cater to local needs and create new market value.
See More
SBC Medical Group Q1 2026 Earnings Call Insights
- Revenue Decline Analysis: Total revenues for Q1 2026 were $43 million, reflecting a 9% year-over-year decline primarily due to fee structure revisions implemented in April last year, which negatively impacted franchising revenue by $6.2 million and management services revenue by $2.4 million, totaling an $8.7 million decrease, indicating challenges in revenue structure adjustments.
- Profitability Decline: Net income decreased year-over-year, partly due to a one-time life insurance gain of $8.7 million in the prior year; however, excluding the impact of fee structure revisions, underlying revenue grew by 11% year-over-year, demonstrating potential business resilience.
- AI Strategy Advancement: The company is promoting an AI initiative aimed at driving top-line growth through enhanced customer experiences while also enabling a leaner, more efficient organization, with management expressing optimism about future growth as the impact of fee structure adjustments rolls off.
- Cash Flow and Investment Priorities: Management emphasized that while the current share repurchase program is not a priority, the company has a strong cash position and plans to prioritize growth investments, particularly in seeking M&A opportunities within the competitive Japanese aesthetic market.
See More
SBC Medical Group Q1 Earnings Report
- Earnings Highlights: SBC Medical Group reported a Q1 GAAP EPS of $0.11, reflecting resilience in the current market despite a 9.1% year-over-year decline, indicating ongoing profitability amidst challenges.
- Revenue Performance: The company generated $43 million in revenue for Q1, down 9.1% year-over-year and missing market expectations by $5.87 million, highlighting challenges in revenue growth that could impact investor confidence moving forward.
- Secondary Offering Announcement: SBC Medical announced a secondary offering of 3.1 million shares by a selling stockholder, aimed at strengthening its capital structure and providing funding for future expansion, demonstrating a proactive approach to market opportunities.
- Analyst Ratings: While the Q1 GAAP EPS of $0.14 beat expectations by $0.03, the revenue of $39.57 million fell short of projections, reflecting a cautious market sentiment regarding the company's future performance and potential stock price implications.
See More
SBC Medical Reports Q1 2026 Financial Results with Significant Declines
- Revenue Decline: In Q1 2026, total revenues were $43 million, reflecting a 9% year-over-year decrease primarily due to a franchise fee structure reform implemented in April 2025, indicating challenges in revenue growth for the company.
- Significant Net Income Drop: Net income attributable to SBC Medical was $11 million, a 47% year-over-year decline, with a net income margin of 26%, down 19 percentage points from the previous year, highlighting a substantial weakening in profitability.
- Customer Growth and Retention: Despite revenue challenges, the number of customers reached 6.76 million over the past twelve months, a 10% year-over-year increase, with a repeat visit rate of 72%, indicating the company's continued market appeal in customer retention.
- Future Strategic Direction: The company plans to advance its multi-brand strategy, expand its non-aesthetic medical business, and enhance service quality through AI utilization, aiming to adapt to market changes and achieve sustainable growth.
See More
European Stock Market Volatility and Undervalued Stocks Analysis
- Market Volatility Analysis: The European stock market has recently experienced volatility, with the pan-European STOXX Europe 600 Index posting modest gains as investor sentiment was buoyed by easing geopolitical tensions and strong corporate earnings, indicating a search for stability amidst uncertainty.
- Undervalued Stocks Identification: In the current market environment, identifying undervalued stocks is crucial, particularly those potentially trading below their intrinsic value, allowing investors to optimize their portfolios through these opportunities.
- SNGN Romgaz Financial Overview: SNGN Romgaz SA has a market cap of RON 52.03 billion, with full-year sales reaching RON 8.03 billion and net income at RON 3.35 billion in 2022, while projected annual growth of 10.9% indicates strong competitiveness in the Romanian market.
- Alleima Future Outlook: Alleima AB is currently trading at SEK 83.70, significantly below its estimated future cash flow value of SEK 112.76, and despite a decline in first-quarter sales to SEK 4.58 billion, it is expected to grow at an annual rate of 28%, far exceeding the Swedish market's average of 8.9%.
See More
SBC Medical Group to Release Q1 2026 Financial Results
- Earnings Release Schedule: SBC Medical Group plans to release its financial results for the first quarter ended March 31, 2026, before the U.S. market opens on May 14, 2026, which is expected to provide investors with key financial data and operational performance insights.
- Conference Call Details: Management will host an earnings conference call on the same day at 8:30 a.m. Eastern Time, followed by a Q&A session with analysts and investors, aimed at enhancing transparency and fostering engagement with stakeholders.
- Company Background: SBC Medical Group is a Medical Services Organization providing management support across various healthcare fields, including aesthetic healthcare and orthopedics, actively expanding its presence in the U.S. and Asia, demonstrating its commitment to a global strategy.
- NASDAQ Listing Achievement: Since its listing on NASDAQ in September 2024, SBC Medical Group was included in the Russell 3000® Index in June 2025, marking an increase in its recognition and influence within the U.S. equity market.
See More
